Tibet Weixinkang Medicine Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Tibet Weixinkang Pharmaceutical Co., Ltd. was established in 2006. After years of development, the company's strength has continuously strengthened and has grown into a comprehensive high-tech pharmaceutical industry group with 11 subsidiaries, covering product and technology research and development, drug production and manufacturing, and sales. The company was listed on the main board of the Shanghai Stock Exchange in 2017 (securities code 603676). The company's product research and development has closely followed the changes in clinical demand, based on the strategy of development and innovation, adhering to the combination of imitation and innovation, and has formed obvious advantages in various professional fields. It has successfully cultivated a batch of drug varieties with precise clinical efficacy and broad market prospects, and has increased its market share through multiple segmented product brands. At present, the company's leading products include multiple vitamins for injection (12), multiple vitamins for pediatric injection (13), multiple trace element injection, potassium magnesium aspartate injection, sucrose iron injection, compound electrolyte injection (II), compound electrolyte injection (V), mixed sugar electrolyte injection, potassium aspartate injection, and other products. A systematic core capability has been formed in the construction of research and development technology platforms, acquisition and updating of product information, upgrading of research and development equipment and management. The company has established a professional and efficient market sales network, effectively supporting the marketing and sales of existing and new products. The business system has covered more than 2000 secondary or above terminal medical institutions nationwide, covering mainstream commercial channels and the vast majority of provinces in China. The company has always adhered to the talent concept of "people-oriented, striving for excellence together", attracting a large number of professional talents to join, laying a solid talent foundation for the company's long-term development. In the future, the company will keep in mind its mission of caring for life and maintaining health, further comply with national pharmaceutical industry policies and industry trends, continuously improve its innovation capabilities and technological level, expand its product development direction, provide more innovative and accessible treatment plans, and promote the company to move towards a modern and large-scale high-tech pharmaceutical industry. It is committed to becoming a professional and innovative pharmaceutical enterprise respected by Chinese society and the public. |
| Headquarter | Lhasa City |
| Establish Date | 3/17/2006 |
| Listed Code | 603676.SH |
| Listed Date | 7/21/2017 |
| Chairman | Zhang Yong. |
| CEO | Zhang Yong. |
| Website | www.wxkpharma.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
